A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of Olverembatinib combined with chemotherapy versus Imatinib combined with chemotherapy in subjects with newly diagnosed Ph+ALL.
Epistemonikos ID: ff1fef2eb87d588acd37267b9e700ffa6373c00e
First added on: May 15, 2024